Q2 2026 STAAR Surgical Company Earnings Call Transcript
Key Points
- Record first-half revenue performance, with Q2 net sales up 111% year-over-year to $93.5 million.
- Strong growth in China driven by EVO Plus launch, with market share gains and no evidence of inventory build.
- Back-to-back record quarters in the US, with double-digit growth in the Americas and EMEA (ex-Middle East).
- Return to profitability and significant cash generation, with cash balance increasing to $181.5 million and no debt.
- Successful ERP implementation and progress on innovation, including preparation for first-in-human studies on next-generation products.
- Q3 2026 comparisons will be impacted by the non-repeat of a $25.9 million one-time order from Q3 2025, requiring an adjusted base for growth evaluation.
- China refractive market remains uneven, with overall market growth only mid-single digits and pressure from declining laser procedures.
- Currency headwinds in Japan dampened reported sales growth despite strong unit volume growth of 14%.
- Gross margin negatively impacted by China tariffs on US-manufactured product, expected to persist until end of 2026.
- Supply chain constraints, particularly for EVO Plus and made-to-order lenses, have led to backorders and potential lost sales in the US.
Welcome to the STAAR Surgical second-quarter 2026 results conference call and webcast.
(Operator Instructions)
Please note this event is being recorded. I would now like to turn the conference over to Connie Johnson, Director of Investor Relations.
Thank you, operator. Good afternoon and thank you for joining us. On the call today are Warren Foust, President and Chief Executive Officer of STAAR Surgical, and Deborah Andrews, Executive Vice President, and Chief Financial Officer of STAAR Surgical.
Earlier today, we reported our second-quarter 2026 results via a press release in Form 8-K. We posted our results, release, and shareholder letter to our investor website at investors.staar.com. Today's call is scheduled for one hour and will include Q&A for publishing analysts. Webcast participants can also send questions for today's Q&A session to [email protected].
Before we get started, I want to remind you that during today's discussion, we will be making
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
